Study of LM-299 in Subjects Advanced Malignant Tumors
ConditionMalignant Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLaNova Medicines Limited
About this trial
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours..
For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.
Eligibility criteria
Qualifiers
Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
Participant must be 18- 18 years or the legal age of consent at the time of signing the ICF.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancy ≥ 3 months.
Disqualifiers
Participate in any other clinical trial within 28 days prior to 1st dosing of LM-299.
Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-299.
Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
Subjects with uncontrolled tumour-related pain.
Trial design
Treatments tested in this trial
- LM-299
Treatment groups
108 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov